Synergy Pharmaceuticals (NASDAQ:SGYP) beat the odds by successfully winning FDA approval of Trulance last year, but it may not matter. Recently, management warned it's struggling to renegotiate its debt, and that increases the risk of its bankruptcy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,